New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2012
16:58 EDTPFCB, SHLD, PBY, IDTI, PFE, HLF, PLXT, CHKOn The Fly: Closing Wrap
Stocks on Wall Street were higher following an encouraging report on U.S. manufacturing. Stock futures were quiet during the pre-market trading session as investors digested the latest round of corporate earnings without having to deal with any new economic reports. The futures action led to a relatively quiet open for the broader market. The market received a lift following the ISM manufacturing report, which was better than expected. The data lifted to the market to fresh recovery highs on the Dow while recent highs were also within striking distance for the Nasdaq and S&P. The market met resistance at the new levels and pared its gains in the afternoon hours... ECONOMIC EVENTS: Domestically, the ISM manufacturing index rose to 54.8 in April, beating forecasts for a reading of 53.0. Construction spending for March increased by 0.1%, versus expectations of an increase of 0.5%. In China, the official purchasing managers’ index for manufacturing rose to 53.3 in April... COMPANY NEWS: Chesapeake (CHK) said it would appoint a new non-executive chairman in the near future to replace CEO Aubrey McClendon in that role. McClendon, who will remain on as CEO, also agreed to an early termination of the well participation program that has drawn a firestorm of recent backlash from media, investors and regulators. Shares gained $1.16, or 6.29%, to close at $19.60 ahead of the company's earnings report, due out after the bell... Dow component Pfizer (PFE) reported earnings that beat consensus but lowered its full year forecast to account for the divestiture of its Nutrition business... Sears Holdings (SHLD) gained $8.27, or 15.38%, to $62.05 after saying its Q1 domestic same store sales fell 1.3%, which was a significant improvement from the declines seen in the same period last year, and forecasting a return to earnings from continuing operations in the quarter... MAJOR MOVERS: Among the notable gainers were PLX Technology (PLXT), up $2.68, or 67.34%, to $6.66, after saying it will be acquired by Integrated Device Technology (IDTI) for $7 per share in cash and stock, and P.F. Chang's (PFCB), up $11.79, or 29.71%, to $51.48, on news it will be acquired and taken private by Centerbridge Partners for $51.50 per share in cash. Noteworthy losers included Herbalife (HLF), down $14.02, or 19.94%, to $56.30, after hedge fund manager and noted short-seller David Einhorn asked some critical questions during the company's earnings conference call, and Pep Boys (PBY), down $3.31, or 22.17%, to $11.62, after the Gores Group hinted it may attempt to walk away from its proposed $1B takeover of the company following Pep Boys' warning on its Q1 results... INDICES: The Dow gained 65.69, or 0.50%, to 13,279.32; the Nasdaq rose 4.08, or 0.13%, to 3,050.44; and the S&P 500 added 7.91, or 0.57%, to 1,405.82.
News For CHK;PFE;SHLD;PLXT;IDTI;PFCB;HLF;PBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 26, 2015
13:09 EDTHLFPershing Square urges Herbalife CEO to release video referenced by NY Post
Pershing Square Capital released a letter it sent to Herbalife CEO Michael Johnson concerning his "serious admissions about Herbalife and its conduct that were revealed by the New York Post." The letter states in part: "Today the New York Post reported on a 71-minute video in which you appear on a stage, making serious admissions about Herbalife and its conduct...We urge that you release the 71-minute video and any similar materials in your possession or control, and we encourage Herbalife employees, distributors and others with similar materials to come forward...In February 2013, we publicly asked you to provide simple data on how many people arrive and leave at each level of Herbalife’s network over time...You still have not disclosed the facts. In light of your admission that Herbalife is a lottery ticket, basic fairness suggests you should disclose the facts."
08:56 EDTHLFVideo shows Herbalife CEO saw ‘pyramiding’ signs in 2005, NY Post reports
Subscribe for More Information
June 25, 2015
16:00 EDTCHKOptions Update; June 25, 2015
Subscribe for More Information
15:48 EDTCHKChesapeake options active as share trend lower
Chesapeake July 11 and 12 puts are active on total put volume of 59K contracts (43K puts). July call option implied volatility is at 42, August is at 44; compared to its 52-week range of 23 to 68. Active put volume suggests traders taking positions for large price movement.
10:07 EDTHLFHerbalife rises after Pivotal says SEC completes review of filings
Subscribe for More Information
10:00 EDTCHKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:47 EDTHLFHerbalife price target raised to $90 from $80 at Pivotal Research
Subscribe for More Information
05:56 EDTCHKChesapeake downgraded to Sell from Neutral at UBS
UBS analyst William Featherston downgraded Chesapeake Energy (CHK) to Sell after his firm cut its long-term normalized natural gas price forecast to $4.00 from $4.50. Featherston thinks Chesapeake carries "far too much financial leverage" and he views the shares as expensive relative to peers. The analyst cut his price target for the stock to $11 from $16. Shares of the natural gas producer closed yesterday down 22c to $11.56. Featherston coupled the downgrade with an upgrade of Marathon Oil (MRO) to Buy.
June 24, 2015
13:23 EDTPFEPfizer says CDC committee votes to recommend MenB vaccine
Pfizer announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted to recommend that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with healthcare providers. It added, "Specifically, the ACIP voted that a serogroup B meningococcal vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years of age." Pfizer's Trumenba is FDA-approved for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. The ACIP recommendation will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval, Pfizer said.
11:11 EDTSHLDAnalyst says Best Buy shares poised to rise
Best Buy's (BBY) stock is poised to advance after the company reports its second quarter results, research firm B. Riley predicted. WHAT'S NEW: Best Buy's forecast for increased margins in the second half of the year, along with easing comparisons, should cause the stock to rise, predicted B. Riley in a note to investors earlier today. The shares will be particularly well-positioned to climb after the company updates its guidance following its Q2 results, the firm believes. Best Buy's initiatives should help increase its revenue and profits heading into fiscal 2017 and the retailer can continues to increase its market share at the expense of Sears (SHLD), RadioShack and others. Additionally, macro economic trends remain favorable for Best Buy and its key product categories continue to perform well, according to B. Riley. The firm, which is particularly confident about the company's ability to beat Q4 consensus estimates, keeps a $47 price target on the name and reiterates a Buy rating on the shares. WHAT'S NOTABLE: In their own note to investors this morning, SunTrust analysts David Magee and D. Mitch Van Zelfden speculated on potential M&A activity in the specialty retail space, noting that "Wall Street’s appetite for acquisitions has strengthened recently." In their opinion, Best Buy acquiring GameStop (GME) is among the "most compelling relationships" in the sector, the note explained. PRICE ACTION: In mid-morning trading, Best Buy slid 0.4% to $34.72, while GameStop rose 1.3% to $44.92.
11:02 EDTPFEPfizer lung cancer treatment granted FDA orphan drug designation
Subscribe for More Information
09:07 EDTPFECAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
07:35 EDTSHLDCFA Society of Chicago to hold a meeting
Subscribe for More Information
June 23, 2015
14:17 EDTPFEGlycoMimetics to receive $20M payment from Pfizer
Subscribe for More Information
14:01 EDTPFEPfizer announces enrollment of first patient in RESET study
Subscribe for More Information
09:53 EDTPFEPfizer management to meet with FBN Securities
Meeting to be held in New York on June 25 hosted by FBN Securities.
07:25 EDTPFEPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
16:00 EDTCHKOptions Update; June 22, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 17.45. Option volume leaders: AAPL FB BAC CHK WMB BABA TWTR MU AMBA TSLA JPM
08:52 EDTPFEPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
07:01 EDTPFEPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use